LSI Europe

Post-term sheet diligence is when the real work begins. For entrepreneurs, it’s about managing momentum while under a microscope. For medtech investors, it’s about confirming the deal’s risk profile—beyond the pitch deck. “You can’t be surprised with the capital markets where they are,” said Usen. “Sometimes ‘yes’ can turn out to be a really dangerous process if you go on with the wrong partner.” Originally published at: https://www.lsieuropesummit.com/news/venture-capital-due-diligence-what-happens-after-the-verbal-yes  

At LSI Europe, a panel of operators and investors gathered to tackle one of the most complex and consequential challenges facing the industry: how to create, deliver, and capture value in digital health. With new technologies transforming how care is delivered, from telepresence and remote monitoring to robotics and AI, the design of digital health business models has never been more important or more difficult to define. Visit here: https://www.slideshare.net/slideshow/digital-health-business-models-what-investors-and-innovators-want-pdf/283357010

In the medtech world, a “no” from an investor isn’t always what it seems. The decision to pass on a startup often comes down to more than just the technology—it’s a balancing act of risk, timing, and fit. And for the investors themselves, building a smart portfolio means getting comfortable with saying no—a lot. That’s what the panelists unpacked during Investors That Pass—a candid conversation on how venture capitalists make the tough calls regarding medtech portfolio optimization. Drawing from their personal experience, the panelists pulled back the curtain on why even the most promising companies don’t always get a “yes.” Originally published at: https://www.lsieuropesummit.com/news/medtech-portfolio-optimization-why-investors-say-no-and-what-that-really-means